Stock Analysis
Teva Pharmaceutical Industries Limited (TEVA) Stock Analysis
Teva Pharmaceutical Industries Limited (TEVA) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Teva Pharmaceutical Industries Limited (TEVA) currently has an AIQ Score of 52/100, indicating a neutral setup. Sentiment is the strongest factor at 67/100. Quality is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
TEVA at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $36.36 |
| AIQ Score | 52/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Neutral |
| Market Cap | $42.15B |
| P/E Ratio | 12.35 |
| Forward P/E | — |
| EPS | -$0.49 |
| Revenue TTM | $4.14B |
| Dividend Yield | 0.00% |
| Beta | 0.88 |
| Volume | 7.4M |
| 52-week range | $18.21-$38.37 |
| RSI 14 | 49.4 |
| 50-Day SMA | $34.61 |
| 200-Day SMA | $32.57 |
| Analyst Price Target | $43.00 |
| Next Earnings | Nov 4, 2026 |
Create a free account to keep researching stocks
You have viewed 2 stock pages in the last 24 hours. Create a free account to keep researching current evidence.
TEVA
OverviewTEVA Stock Analysis Summary
Teva Pharmaceutical Industries Limited (TEVA) currently has an AIQ Score of 52/100, indicating a neutral setup. Sentiment is the strongest factor at 67/100. Quality is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, TEVA has AIQ Score of 52/100 with Sentiment base of 67/100 and fading Quality at 33/100. Wait for component alignment before adding exposure.
Sentiment (67/100) leads while Quality (33/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.71% stock move · TEVA classified in Drug Manufacturers - Specialty & Generic.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is TEVA Bullish or Bearish Right Now?
TEVA currently has a neutral overall setup. Sentiment is the strongest factor at 67/100, while Quality is weakest at 33/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 60/100.
- - Price is +5.04% above its 50-day SMA.
- - Analyst target implies +18.26% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (20 vs 17).
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
TEVA's Technical Analysis Consensus is currently Neutral, with 20 buy, 8 neutral, and 17 sell votes. TEVA's 14-day RSI is 49.4, which places the stock in a neutral momentum range. TEVA's beta is 0.88, indicating market sensitivity broadly in line with the market.
What Changed in TEVA?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the TEVA Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
TEVA Decision Framework
Public evidence layers, setup checks, and risk context for Teva Pharmaceutical Industries Limited.
Teva Pharmaceutical Industries Limited (TEVA) Stock Analysis
Teva Pharmaceutical Industries Limited has an AIQ Score of 52/100 in a Neutral regime. Sentiment is strongest at 67/100. Beta is 0.88, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | TEVA is in a Neutral AIQ regime with score 52/100. |
| Signal Conflict | The primary conflict is that sentiment leads at 67/100 while quality lags at 33/100. |
| Factor Evidence | Momentum 60/100 · Value 65/100 · Quality 33/100 · Risk 53/100 · Sentiment 67/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Sentiment is the strongest factor at 67/100.
Momentum is 60/100 and RSI (14) is 49.4.
TEVA is in a Neutral regime at 52/100.
Risk factor is 53/100 with beta 0.88 and annual volatility 39.91%.
Current conflict: sentiment leads at 67/100 while quality lags at 33/100.
TEVA Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
TEVA Fundamentals
TEVA valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
TEVA Technical Analysis
TEVA technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
TEVA Stock Catalysts
Track TEVA earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
TEVA Dividend Analysis
TEVA dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
TEVA Financial Data
TEVA revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
TEVA Risk Analysis
TEVA volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
TEVA Stock News
TEVA stock news, market tone, recent headlines, and catalyst context.
TEVA vs Large Cap Pharma Peers
Current peer cohort: TEVA · VRTX · ABBV · AMGN · AZN. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| TEVA Current stock | 52/100 | 65/100 | 60/100 | 53/100 | 1.8 | 39.91% | Current |
| VRTX Vertex Pharmaceuticals | 62/100 | 32/100 | 72/100 | 62/100 | 1.12 | 28.63% | TEVA vs VRTX |
| ABBV AbbVie | 52/100 | 36/100 | 65/100 | 44/100 | 0.69 | 26.62% | TEVA vs ABBV |
| AMGN Amgen | 58/100 | 44/100 | 66/100 | 50/100 | 1.61 | 27.66% | TEVA vs AMGN |
| AZN AstraZeneca | 58/100 | 53/100 | 52/100 | 48/100 | -0.02 | 28.31% | TEVA vs AZN |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 5, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 7, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching TEVA
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for TEVA
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
TEVA Stock FAQ
What is TEVA stock price today?
Teva Pharmaceutical Industries Limited's current stock price is $36.36. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is TEVA bullish or bearish right now?
TEVA's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is TEVA's market cap?
TEVA's market cap is $42.15B based on the latest completed market-close snapshot from Sep 4, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is TEVA's current P/E ratio?
TEVA's current P/E ratio is 12.35 based on the latest completed market-close snapshot from Sep 4, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is TEVA's RSI?
TEVA's 14-day RSI is 49.4 based on the latest completed market-close snapshot from Sep 4, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is TEVA above its 50-day and 200-day moving averages?
TEVA is 5.04% from its 50-day SMA and 11.62% from its 200-day SMA based on the latest completed market-close snapshot from Sep 4, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is TEVA's next earnings date?
TEVA's next earnings date is currently listed as Nov 4, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does TEVA pay a dividend?
TEVA's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 4, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.